8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

May 26, 2005

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

On May 26, 2005, Halozyme Therapeutics, Inc. announced that the U.S. Food and Drug Administration accepted for filing its new drug application (“NDA”) for HylenexÔ. The press release announcing the acceptance of the NDA is attached hereto as Exhibit 99.1 and is incorporated by reference.

Item 9.01 Financial Statements and Exhibits.

      (c) Exhibits.

Exhibit No.	Description
99.1	Press Release dated May 26, 2005.

SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
May 26, 2005	By:	/s/ David A. Ramsay
		David A. Ramsay
		Secretary and Chief Financial Officer

EX-99.1

                                                                    EXHIBIT 99.1

                          (HALOZYME THERAPEUTICS LOGO)

HALOZYME CONTACT                              INVESTOR RELATIONS CONTACTS
David A. Ramsay                               Ina McGuinness / Bruce Voss
Chief Financial Officer                       Lippert/Heilshorn & Associates
(858) 794-8889                                (310) 691-7100
dramsay@halozyme.com                          imcguinness@lhai.com

                                              MEDIA CONTACTS
                                              Kathy Sweeney / Joleen Schultz
                                              Mentus
                                              (858) 455-5500, x230/x215
                                              kwitz@mentus.com
                                              jschultz@mentus.com

                 HALOZYME THERAPEUTICS ANNOUNCES FDA ACCEPTANCE
                                 OF HYLENEX NDA

SAN DIEGO, MAY 26, 2005 - Halozyme Therapeutics, Inc. (AMEX: HTI), a development
stage biopharmaceutical company focused on the development and commercialization
of recombinant human enzymes, today announced that the U.S. Food and Drug
Administration (FDA) has accepted for filing and review Halozyme's New Drug
Application (NDA) for Hylenex(TM) (formerly referred to as Enhanze SC(TM)).

Halozyme submitted the Hylenex NDA on March 23, 2005, seeking approval for use
as a spreading agent to facilitate the dispersion and absorption of other drugs.
The Company previously announced in April 2005 that the FDA granted Priority
Review status to the Hylenex NDA, which sets the target date for initial FDA
action within six months from the NDA submission date.

"We are excited that the FDA has accepted our NDA filing," said Jonathan Lim,
MD, Halozyme's Chairman and CEO. "This is a significant step in the FDA's review
of Hylenex for use as a spreading agent. If approved by the FDA, we believe
Hylenex could offer physicians an attractive alternative to animal-derived
hyaluronidases."

Halozyme's hyaluronidase (rHuPH20) is a highly purified, recombinant form of the
naturally occurring human enzyme and is being investigated for its ability to
break down hyaluronic acid (HA), the space-filling "gel"-like substance that is
a major component of tissues throughout the body. Hyaluronidase that is injected
in the skin or in the muscle can temporarily digest the HA gel to enhance the
penetration and diffusion of other injected drugs or fluids.






ABOUT HALOZYME THERAPEUTICS, INC.
Halozyme is a development stage biopharmaceutical company dedicated to
developing and commercializing recombinant human enzymes for the infertility,
ophthalmology, and oncology communities. The company's portfolio of products
under development is based on intellectual property covering the family of human
enzymes known as hyaluronidases. Halozyme's recombinant human enzymes may
replace current animal slaughterhouse-derived enzymes that carry potential risks
of animal pathogen transmission and immunogenicity. The versatility of the first
enzyme, rHuPH20, enables Halozyme to develop the product as a medical device,
drug enhancement agent, and therapeutic biologic.

SAFE HARBOR STATEMENT
In addition to historical information, the statements set forth above include
forward-looking statements (including, without limitation, statements concerning
the Company's products under development, the timing of expected regulatory
filings, and the regulatory approval of products under development) that involve
risk and uncertainties that could cause actual results to differ materially from
those in the forward-looking statements. The forward-looking statements are also
identified through use of the words "believe," "enable," "may," "will," "could,"
"intends," "estimate," "anticipate," "plan," "predict," "probable," "potential,"
"possible," "should," "continue," and other words of similar meaning. Actual
results could differ materially from the expectations contained in
forward-looking statements as a result of several factors, including regulatory
approval requirements and competitive conditions. These and other factors that
may result in differences are discussed in greater detail in the company's
reports on Forms 10-KSB, 10-QSB and other filings with the Securities and
Exchange Commission.

                                      # # #